The clinical research of Apatinib for the treatment of advanced non-small cell lung cancer
Latest Information Update: 17 May 2017
Price :
$35 *
At a glance
- Drugs Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 May 2017 New trial record